NASDAQ:UTHR
UNITED THERAPEUTICS Corp
UNITED THERAPEUTICS Corp's revenue grew 10.6% in fiscal 2025 to $3.2B while operating margin fell to 46.9%. Free cash flow was $1.0B, 32.7% of revenue, and the diluted share count fell 1.2%.Summary generated from UNITED THERAPEUTICS Corp's SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.2B
Revenue growth+10.6%
Revenue, 5-yr CAGR+16.5%
Gross margin87.9%
Operating margin46.9%
Net margin41.9%
ROICn/a
Return on equity19.7%
Debt / equityn/a
Free cash flow$1.0B
FCF margin32.7%
Share count change−1.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,686 | 1,936 | 2,328 | 2,877 | 3,183 |
| Operating income | 556 | 980 | 1,185 | 1,377 | 1,493 |
| Net income | 476 | 727 | 985 | 1,195 | 1,335 |
| Free cash flow | 477 | 664 | 748 | 1,081 | 1,041 |
Recent filings
- 4Insider transaction report
Oct 9, 2026 - 4Insider transaction report
Oct 8, 2026 - 8-KEntry into a material agreement
Sep 8, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KDirector or officer change
Jul 23, 2026 - 8-KDirector or officer change
Jun 29, 2026 - 8-KResults of operations and financial condition
May 6, 2026